205 related articles for article (PubMed ID: 23528371)
61. Peripheral T-cell lymphomas.
Savage KJ
Blood Rev; 2007 Jul; 21(4):201-16. PubMed ID: 17512649
[TBL] [Abstract][Full Text] [Related]
62. Pralatrexate (Folotyn).
Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
[TBL] [Abstract][Full Text] [Related]
63. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
64. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
65. Investigational drugs for T-cell lymphoma.
Ghez D; Danu A; Ribrag V
Expert Opin Investig Drugs; 2016; 25(2):171-81. PubMed ID: 26576861
[TBL] [Abstract][Full Text] [Related]
66. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
[TBL] [Abstract][Full Text] [Related]
67. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
Blystad AK; Enblad G; Kvaløy S; Berglund A; Delabie J; Holte H; Carlson K; Kvalheim G; Bengtsson M; Hagberg H
Bone Marrow Transplant; 2001 Apr; 27(7):711-6. PubMed ID: 11360110
[TBL] [Abstract][Full Text] [Related]
68. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
69. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review.
Rodriguez-Abreu D; Filho VB; Zucca E
Hematol Oncol; 2008 Mar; 26(1):8-20. PubMed ID: 18050364
[TBL] [Abstract][Full Text] [Related]
70. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis.
Yin J; Wei J; Xu JH; Xiao Y; Zhang YC
Acta Haematol; 2014; 131(2):114-25. PubMed ID: 24158006
[TBL] [Abstract][Full Text] [Related]
71. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.
Franco CM; Popplewell LL; Horwitz SM
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001
[TBL] [Abstract][Full Text] [Related]
72. Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion.
Said J; Pinter-Brown L
Clin Adv Hematol Oncol; 2009 Nov; 7(11):S1, S4-13; quiz S15. PubMed ID: 20095101
[TBL] [Abstract][Full Text] [Related]
73. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
74. [Current treatment strategies for peripheral T-cell lymphoma].
Munakata W
Rinsho Ketsueki; 2021; 62(8):1112-1120. PubMed ID: 34497198
[TBL] [Abstract][Full Text] [Related]
75. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
Gisselbrecht C; Sibon D
Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
[TBL] [Abstract][Full Text] [Related]
76. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
[TBL] [Abstract][Full Text] [Related]
77. Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y; Li X; Luan Y; Luo J; Dong Q; Ye S; Li Y; Li Y; Jia L; Yang J; Yang DH
Mol Cancer; 2024 Jan; 23(1):2. PubMed ID: 38178117
[TBL] [Abstract][Full Text] [Related]
78. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.
Reimer P; Chawla S
J Hematol Oncol; 2013 Sep; 6():69. PubMed ID: 24020452
[TBL] [Abstract][Full Text] [Related]
79. PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
Han X; Liu X; Zhang C; Wen Q; Zhang X
J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938
[TBL] [Abstract][Full Text] [Related]
80. Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study.
Farhan A; Chong EA; Schuster SJ; Strelec L; Nasta SD; Landsburg D; Svoboda J
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):109-115. PubMed ID: 30448048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
